Sarah Ketterer's GSK Position Overview
Sarah Ketterer (via Causeway Capital Management LLC) currently holds 33,897 shares of GSK plc (GSK) worth $1.66 M, representing 0.02% of the portfolio. First purchased in 2022-Q2, this medium-term investment has been held for 15 quarters.
Based on 13F filings, Sarah Ketterer has maintained a strategic position in GSK, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2023, adding 230,694 shares. Largest reduction occurred in Q4 2025, reducing 1.14 M shares.
Analysis based on 13F filings available since 2013 Q2
Sarah Ketterer's GSK plc (GSK) Holding Value Over Time
Track share changes against reported price movement
Quarterly GSK plc (GSK) Trades by Sarah Ketterer
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -1.14 M | Reduce 97.12% | 33,897 | $49.04 |
| Q3 2025 | +69,925 | Add 6.32% | 1.18 M | $43.16 |
| Q2 2025 | -847 | Reduce 0.08% | 1.11 M | $38.40 |
| Q1 2025 | +31,343 | Add 2.91% | 1.11 M | $38.74 |
| Q4 2024 | +179,174 | Add 19.97% | 1.08 M | $33.82 |
| Q3 2024 | +143,871 | Add 19.09% | 897,406 | $40.88 |
| Q2 2024 | +16,350 | Add 2.22% | 753,535 | $38.50 |
| Q1 2024 | -58,256 | Reduce 7.32% | 737,185 | $42.87 |
| Q4 2023 | +230,694 | Add 40.85% | 795,441 | $37.06 |
| Q3 2023 | +165,317 | Add 41.39% | 564,747 | $36.25 |
| Q2 2023 | +80,270 | Add 25.15% | 399,430 | $35.64 |
| Q1 2023 | +82,127 | Add 34.65% | 319,160 | $35.58 |
| Q4 2022 | +53,489 | Add 29.14% | 237,033 | $35.14 |
| Q3 2022 | -22,986 | Reduce 11.13% | 183,544 | $29.43 |
| Q2 2022 | +206,530 | New Buy | 206,530 | $54.41 |
Sarah Ketterer's GSK plc Investment FAQs
Sarah Ketterer first purchased GSK plc (GSK) in Q2 2022, acquiring 206,530 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Sarah Ketterer has held GSK plc (GSK) for 15 quarters since Q2 2022.
Sarah Ketterer's largest addition to GSK plc (GSK) was in Q4 2023, adding 795,441 shares worth $29.48 M.
According to the latest 13F filing for Q4 2025, Sarah Ketterer's firm, Causeway Capital Management LLC, owns 33,897 shares of GSK plc (GSK), valued at approximately $1.66 M.
As of the Q4 2025 filing, GSK plc (GSK) represents approximately 0.02% of Sarah Ketterer's publicly disclosed stock portfolio, making it one of their key holdings.
Sarah Ketterer's peak holding in GSK plc (GSK) was 1,177,001 shares, as reported at the end of Q3 2025.